Israel - inglés - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 40 mg - valsartan - valsartan - diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan significantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - inglés - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 80 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - inglés - Ministry of Health

novartis israel ltd - valsartan - film coated tablets - valsartan 160 mg - valsartan - valsartan - for treatment of hypertension. diovan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial diovan signicantly reduced hospitalisations for heart failure. there is no evidence that diovan provides added benefits when it is used with an adequate dose of an ace inhibitor. diovan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.

Israel - inglés - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Israel - inglés - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - valsartan - film coated tablet - 80 milligram - angiotensin ii antagonists, plain

Australia - inglés - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Australia - inglés - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 40 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Australia - inglés - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red; iron oxide black - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").

Australia - inglés - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; titanium dioxide; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - treatment of hypertension. treatment of heart failure (nyha class ii-iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction (see "clinical trials").